



FOR IMMEDIATE RELEASE

Tokyo, December 1, 2025

Notice Regarding Completion of JT Group's Pharmaceutical Business to

Shionogi & Co., Ltd. through a Company Simplified Absorption-Type Split

Japan Tobacco Inc. ("JT") (TSE: 2914) announces that the transfer of JT Group's Pharmaceutical

Business to Shionogi & Co., Ltd. has been completed today. This transfer was conducted through a Company Simplified Absorption-Type Split, in accordance with the "Notice regarding the transfer of

JT Group's Pharmaceutical Business through a company simplified absorption-type split" which

was previously announced on May 7, 2025, and the "Notice Regarding the Conclusion of an

Absorption-Type Split Contract Related to the Transfer of JT Group's Pharmaceutical Business to

Shionogi & Co., Ltd. Through a Company Simplified Absorption-Type Split"** which was previously

announced on September 25, 2025.

###

Japan Tobacco Inc. (JT) is a global company headquartered in Tokyo, Japan. It is listed on the primary section

of the Tokyo Stock Exchange (ticker: 2914.T). JT Group has approximately 53,000 employees and 61 factories

worldwide, operating in two business segments: tobacco and processed food. Within the tobacco business, the

largest segment, products are sold in over 130 markets and its flagship brands include Winston, Camel, MEVIUS,

and LD. The Group is committed to investing in Reduced-Risk Products and markets its heated tobacco products

under its Ploom brand.

Consumers, shareholders, employees, and society are the four stakeholder groups (4S) at the heart of all of JT

Group's activities. Inspired by its "Fulfilling Moments, Enriching Life" purpose, the Group aims to ensure

sustainable and valuable contributions to its stakeholders over the long term. In addition to our two business

segments, this goal is also supported by D-LAB, the JT Group's corporate R&D initiative, set up to search and

create added-value business opportunities. For more information, visit https://www.jt.com/.

Contacts:

Yunosuke Miyata, Director

Investor & Media Relations Division

Japan Tobacco Inc.

Tokyo: +81-3-6636-2914

E-mail: jt.media.relations@jt.com

https://www.jt.com/media/news/2025/pdf/20250507 12.pdf

** https://www.jt.com/media/news/2025/pdf/20250925 E01.pdf